Entering text into the input field will update the search result below

Early-stage study commences for Prana's lead drug PBT434; shares ahead 22%

Jul. 05, 2018 10:40 AM ETAlterity Therapeutics Limited (ATHE) StockBy: Douglas W. House, SA News Editor1 Comment
  • Thinly traded nano cap Prana Biotechnology Ltd (PRAN +21.9%) is up on a healthy 32x surge in volume on the heels of its announcement that dosing is underway in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of Parkinson's disease (PD) candidate PBT434 in healthy volunteers.
  • PBT434 belongs to a class of molecules called quinazolinones which block the accumulation and aggregation of a protein called alpha-synuclein which is associated with PD and Lewy body dementia.

Recommended For You

About ATHE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ATHE--
Alterity Therapeutics Limited